» Articles » PMID: 29018690

When is Macular Edema Not Macular Edema? An Update on Macular Telangiectasia Type 2

Overview
Specialty Ophthalmology
Date 2017 Oct 12
PMID 29018690
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Macular telangiectasia type 2 (Mac Tel 2) also known as idiopathic perifoveal telangiectasia and juxtafoveolar retinal telangiectasis type 2A is an enigmatic disease of unknown etiology. It manifests both neurodegenerative and vasculopathic characteristics. It manifests itself during the fifth or sixth decades of life. Clinical characteristics include minimally dilated parafoveal capillaries with loss of the retinal transparency in the area involved, absence of lipid exudation, right-angled retinal venules, superficial retinal refractile deposits, hyperplasia of the retinal pigment epithelium (RPE), foveal atrophy and subretinal neovascularization (SRNV). Optical coherence tomography (OCT) images typically demonstrate outer retinal abnormalities and the presence of intra-retinal hyporeflective spaces that are usually not related with retinal thickening or fluorescein leakage. The typical fluorescein angiographic finding is a deep intraretinal hyperfluorescent staining in the temporal parafoveal area. With time this fluorescein hyperfluorescence involves the whole parafoveal area but does not extend to the center of the fovea. Long-term prognosis for central vision is poor, because of the development of SRNV or macular atrophy. Its pathogenesis remains unclear but multi-modality imaging with fluorescein angiography, spectral domain OCT, adaptive optics, confocal blue reflectance, short wave fundus autofluorescence, OCT angiography, and clinicopathological correlations implicate Müller cells. Currently there is no known treatment for this condition.

Citing Articles

Unraveling the mysteries of macular telangiectasia 2: the intersection of philanthropy, multimodal imaging and molecular genetics. The 2022 founders lecture of the pan American vitreoretinal society.

Wu L Int J Retina Vitreous. 2023; 9(1):69.

PMID: 37968753 PMC: 10652610. DOI: 10.1186/s40942-023-00505-5.


The Role of Diagnostic Imaging in Macular Telangiectasia Type 2.

Zerbinopoulos B, Goman-Baskin E, Greenberg P, Bryan R, Messina C Fed Pract. 2022; 38(12):594-597.

PMID: 35177889 PMC: 8843004. DOI: 10.12788/fp.0200.


Case report: internal limiting membrane drape sign masking by foveal detachment in macular telangiectasia type 2.

Abdul-Rahman A BMC Ophthalmol. 2020; 20(1):213.

PMID: 32493257 PMC: 7268351. DOI: 10.1186/s12886-020-01485-y.


Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.

Karasu B, Gunay B Graefes Arch Clin Exp Ophthalmol. 2019; 258(1):99-106.

PMID: 31768680 DOI: 10.1007/s00417-019-04520-x.


Choose the right treatment for the right patients.

Sheu S Taiwan J Ophthalmol. 2017; 5(4):147-148.

PMID: 29018689 PMC: 5602131. DOI: 10.1016/j.tjo.2015.10.001.

References
1.
Finger R, Charbel Issa P, Fimmers R, Holz F, Rubin G, Scholl H . Reading performance is reduced by parafoveal scotomas in patients with macular telangiectasia type 2. Invest Ophthalmol Vis Sci. 2008; 50(3):1366-70. DOI: 10.1167/iovs.08-2032. View

2.
Koizumi H, Iida T, Maruko I . Morphologic features of group 2A idiopathic juxtafoveolar retinal telangiectasis in three-dimensional optical coherence tomography. Am J Ophthalmol. 2006; 142(2):340-3. DOI: 10.1016/j.ajo.2006.03.021. View

3.
Sanchez J, Garcia R, Wu L, Berrocal M, Graue-Wiechers F, Rodriguez F . Optical coherence tomography characteristics of group 2A idiopathic parafoveal telangiectasis. Retina. 2007; 27(9):1214-20. DOI: 10.1097/IAE.0b013e318074bc4b. View

4.
Liang J, Williams D, Miller D . Supernormal vision and high-resolution retinal imaging through adaptive optics. J Opt Soc Am A Opt Image Sci Vis. 1997; 14(11):2884-92. DOI: 10.1364/josaa.14.002884. View

5.
Wu L . Multimodality imaging in macular telangiectasia 2: A clue to its pathogenesis. Indian J Ophthalmol. 2015; 63(5):394-8. PMC: 4501134. DOI: 10.4103/0301-4738.159864. View